1. Perspectives on Key MS Data From the Annual Neurology Meeting

2. Introduction

3. Alemtuzumab

4. CARE MS II Extension: Efficacy

5. CARE MS II Extension: Safety

6. CAMMS223 Extension

7. DMF: ENDORSE

8. ENDORSE: Efficacy

9. DR-DMF and Lymphopenia

10. DMF and Lymphopenia

11. Perspectives on Key MS Data From the Annual Neurology Meeting

12. Vitamin D in CIS

13. Modifiable Risk Factors: Smoking

14. Mindfulness and MS

15. Network-Based Cognitive Rehabilitation in RRMS

16. Computer-Assisted Attention Rehabilitation

17. Arbaclofen in Spasticity Treatment

18. Perspectives on Key MS Data From the Annual Neurology Meeting

19. The Effect of Ocrelizumab on MRI Measures: OPERA I and II

20. Teriflunomide and BVL: Few Relapses

21. Teriflunomide and BVL: Greater Relapses

22. BVL in DEFINE, CONFIRM, and ENDORSE

23. CARE-MS I and II Extension Trials: BVL

24. Perspectives on Key MS Data From the Annual Neurology Meeting

25. OPERA I and OPERA II: Efficacy of Ocrelizumab Compared With IFN beta-1a

26. Ocrelizumab Safety Data

27. ORATORIO: Ocrelizumab in Progressive MS

28. Neurophysical Composite Outcome From the DECIDE Study

29. ASCEND: Natalizumab in Progressive MS

30. SYNERGY: Remyelination With Anti-LINGO-1

31. Abbreviations

32. Abbreviations (cont)

33. Abbreviations (cont)